Table 3.
Associations of SHR and NT-proBNP categories with all-cause mortality
| Variable | Events, n/Total | Unadjusted model | Adjusted model | ||
|---|---|---|---|---|---|
| HR (95%CI) | P value | HR (95%CI) | P value | ||
| SHR | < 0.001 | ||||
| Low | 46/574(8.0) | Reference | Reference | ||
| High | 92/574(16.0) | 2.072(1.454–2.952) | 2.046(1.414–2.960) | < 0.001 | |
| NT-proBNP | < 0.001 | ||||
| Low | 36/574(6.3) | Reference | Reference | ||
| High | 102/574(17.7) | 3.021(2.066–4.418) | 5.739(3.365–9.789) | < 0.001 | |
| Combined categories | < 0.001 | < 0.001 | |||
| G1(SHR-L + NT-proBNP-L) | 11/282(3.9) | References | References | ||
| G2(SHR-H + NT-proBNP-L) | 25/292(8.6) | 2.225(1.095–4.522) | 0.027 | 2.372(1.160–4.849) | 0.018 |
| G3(SHR-L + NT-proBNP-H) | 35/292(12.0) | 3.204(1.627–6.308) | 0.001 | 6.587(3.012–14.406) | < 0.001 |
| G4(SHR-H + NT-proBNP-H) | 67/282(23.8) | 6.753(3.569–12.778) | < 0.001 | 12.244(5.828–25.721) | < 0.001 |
SHR stress hyperglycemia, NT-proBNP N-terminal proB-type natriuretic peptide, HR hazard ratio; CI confidential intervals. Adjusted variables included age, smoker, hypertension, previous MI, previous stroke, ACS, LVEF, hemoglobin, TC, TG, HDL-C, LDL-C, hs-CRP, creatinine, three-vessel disease, left main disease, aspirin, and statin